期刊
CURRENT OPINION IN VIROLOGY
卷 52, 期 -, 页码 166-173出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2021.12.002
关键词
-
类别
资金
- Merck Co., Inc.
- Kenilworth, NJ, USA
- Texas Emerging Technology Fund
- Welch Foundation [AU-0042-20030616]
This article discusses the impact and treatment methods of human cytomegalovirus, focusing on the potential use of monoclonal antibodies and the progress in clinical evaluation.
Human cytomegalovirus (HCMV) is a ubiquitous pathogen that can cause permanent childhood disabilities following in utero infection and life threatening diseases in immune-compromised individuals such as those post transplantation. Without an effective vaccine, small molecule antiviral drugs are routinely used in high-risk transplant recipients, but the effectiveness of which is limited by side effects and drug resistance. The potentials of antibody-based passive immune therapies alone or in combination with the small molecule antivirals to treat or prevent HCMV infection have been actively studied. In this review, we focus on the recent publications on identification and characterization of monoclonal antibodies that have the potential to be developed as anti-HCMV therapies. We review the progress in clinical evaluation of antibody-based therapies to prevent HCMV-associated diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据